Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | RORB | Q92753 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.42 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12461333 | 0.89 | RORA (0.49) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL6101006 | 0.87 | RORA (0.50) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL1939226 | 0.86 | PIK3CG (0.56) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL12203598 | 0.85 | RORA (0.51) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL12229089 | 0.85 | RORA (0.51) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL241490 | 0.84 | RORA (0.49) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL12197706 | 0.83 | RORA (0.54) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL1939916 | 0.82 | RORA (0.49) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL12203600 | 0.82 | RORA (0.49) | RORARORCRORBALDH1A1HPGD | |
| SCHEMBL6019728 | 0.81 | RORA (0.46) | RORARORCRORBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3561513-A1 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION | Ventana Medical Systems, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20160362730-A1 | PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS | VENTANA MEDICAL SYSTEMS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9017954-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8445191-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110244545-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. | 2011-10-06 | — | — | US | disclosed |
| US-7985557-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080305497-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | RORA 55/4885RORC 26/4885RORB 34/4885 |
| US-20110244545-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | FCGR2A, CD68, CA14 | RORA 3907/4885RORC 3893/4885RORB 4043/4885 |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | CRBN, AHR, RORB | RORA 7/4885RORC 4/4885RORB 3/4885 |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, GABBR1, SHBG | RORA 8/4885RORC 5/4885RORB 6/4885 |
| US-20080305497-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | FCGR2A, CD68, CA14 | RORA 3907/4885RORC 3893/4885RORB 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.